Open AccessEfficacy and safety of Shenfuqiangxin pills in complementary treatment of chronic heart failure
Author(s) -
Lili Ren,
Hui Guan,
Guo-Hua Dai,
Wulin Gao,
Jing Su
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000024531
Subject(s) - medicine , heart failure , protocol (science) , pill , medline , medical prescription , intensive care medicine , randomized controlled trial , clinical trial , evidence based medicine , alternative medicine , pharmacology , pathology , political science , law
Background: As the last link in the chain of cardiovascular events, chronic heart failure (CHF) has high morbidity, high mortality, and poor prognosis. It is one of the main causes of death and disability worldwide. Shenfuqiangxin Pills (SFQX) is widely used as a Chinese herbal medicine (CHM) prescription for CHF, but there is still a lack of strict evidence-based medical evidence. Therefore, we make a protocol for evaluating the efficacy and safety of SFQX for CHF. Methods: According to the search strategy, randomized controlled trials (RCTs) of SFQX for CHF will be retrieved from 8 databases without limitation of publication date or language. First of all, the literature was screened according to the eligibility criteria, and use the Cochrane Collaboration's tool to assess the quality of the included literature. Then, using software for traditional meta-analysis. Finally, using GRADE method to assess the strength of recommendations. Results: This study will evaluate the efficacy and safety of SFQX for CHF, thereby providing more evidence support for clinical decision-making in CHF. Conclusion: Our research will provide more references for the clinical medication of patients with CHF. Protocol registration number: INPLASY202110019